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Kimikazu Banba, MD, Satoshi Nagase, MD, Hiroshi Morita, MD, Nobuhiro Nishii, MD,
Atsuyuki Watanabe, MD, Takeshi Tada, MD, Masato Murakami, MD, Kohei Miyaji, MD,
Shigeki Hiramatsu, MD, Koji Nakagawa, MD, Masamichi Tanaka, MD, Aya Miura, MD,
Hideo Kimura, MD, Soichiro Fuke, MD, Wakako Sumita, MD, Satoru Sakuragi, MD,
Shigemi Urakawa, MD, Jun Iwasaki, MD, Tohru Ohe, MD, FACC
Okayama, Japan
Objectives The goal of our work was to examine the relationships of atrial fibrillation (AF) with genetic, clinical, and electro-
physiological backgrounds in Brugada syndrome (BrS).
Background Atrial fibrillation is often observed in patients with BrS and indicates that electrical abnormality might exist in
the atrium as well as in the ventricle. SCN5A, a gene encoding the cardiac sodium channel, has been reported
to be causally related to BrS. However, little is known about the relationships of atrial arrhythmias with genetic,
clinical, and electrophysiological backgrounds of BrS.
Methods Seventy-three BrS patients (49  12 years of age, men/women  72/1) were studied. The existence of SCN5A
mutation and clinical variables (syncopal episode, documented ventricular fibrillation [VF], and family history of
sudden death) were compared with spontaneous AF episodes. Genetic and clinical variables were also com-
pared with electrophysiologic (EP) parameters: atrial refractory period, interatrial conduction time (CT), repetitive
atrial firing, and AF induction by atrial extra-stimulus testing.
Results Spontaneous AF occurred in 10 (13.7%) of the BrS patients and SCN5A mutation was detected in 15 patients.
Spontaneous AF was associated with higher incidence of syncopal episodes (60.0% vs. 22.2%, p  0.03) and
documented VF (40.0% vs. 14.3%, p  0.05). SCN5A mutation was associated with prolonged CT (p  0.03)
and AF induction (p  0.05) in EP study, but not related to the spontaneous AF episode and other clinical vari-
ables. In patients with documented VF, higher incidence of spontaneous AF (30.8% vs. 10.0%, p  0.05), AF
induction (53.8% vs. 20.0%, p  0.03), and prolonged CT was observed.
Conclusions Spontaneous AF and VF are closely linked clinically and electrophysiologically in BrS patients. Patients with
spontaneous AF have more severe clinical backgrounds in BrS. SCN5A mutation is associated with electrical ab-
normality but not disease severity. (J Am Coll Cardiol 2008;51:1169–75) © 2008 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.060b
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srugada syndrome (BrS) is a distinct form of idiopathic
entricular fibrillation (VF) characterized by a unique electro-
raphic (ECG) pattern consisting of a right bundle branch
rom the Department of Cardiovascular Medicine, Okayama University Graduate
chool of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. This
ork was supported, in part, by Grant-in-Aid for Scientific Research (No. 18790501),
rant-in-Aid for Young Scientists (No. 17689026) from the Ministry of Education,
ulture, Sports, Science and Technology, Japan and Health Sciences Research grants
H18-Research on Human Genome-002) from the Ministry of Health, Labor and
elfare, Japan. This work was also supported, in part, by a grant from the Japan
oundation of Cardiovascular Research, Tokyo, Japan. Drs. Kusano and Taniyamaa
ontributed equally to this study.
Manuscript received September 19, 2007; accepted October 19, 2007.lock-like morphology and ST-segment elevation in pre-
ordial leads (1–3). In addition to the ventricular arrhythmias,
trial arrhythmias are also often observed in this syndrome
4–6), indicating that electrical abnormality might exist in the
trium as well as in the ventricle.We, therefore, speculated that
atients with BrS and spontaneous atrial fibrillation (AF) have
ore advanced disease process.
See page 1176
The human cardiac sodium channel (SCN5A) is respon-
ible for the fast depolarization upstroke for the cardiac
ction potential (7). Mutations in SCN5A have been previ-
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AF and Brugada Syndrome March 25, 2008:1169–75ously discovered in a wide spec-
trum of cardiac rhythm disor-
ders: the long QT syndrome (8),
BrS (7), sick sinus syndrome
(9,10), cardiac conduction defect
(11), and AF (12). In patients
with BrS, SCN5A mutations
have been reported to be causally
linked to familial BrS (7,13).
However, little is known about
the relationships of atrial ar-
rhythmias with genetic, clinical,
and electrophysiological (EP)
backgrounds. We, therefore, ex-
amined the relationships be-
tween genetic, EP, and clinical
variables to AF in BrS patients.
Methods
Patient population and clinical
data collection. Patients diag-
nosed with BrS in our hospital
between 1997 to 2006 were stud-
ied. All of the tests that were
performed were approved by the
edical ethical review committees of our hospital. Informed
onsent was obtained from all patients. Clinical data,
ncluding data on age at diagnosis, gender, family history,
ocumented VF, syncopal episodes, and implantable
ardioverter-defibrillator (ICD) implantation, were ob-
ained from patient records. Family history of sudden death
FH) was defined as unknown sudden death at less than the
ge of 50 years. All patients showed a typical ECG
Brugada pattern,” which was defined previously (1). If the
tandard ECG pattern showed a type 2 or 3 Brugada pattern,
mg/kg of pilsicainide (a pure sodium channel blocker) was
ntravenously administered for 10 min with continuous mon-
toring in the intensive care unit and it was confirmed that the
rugada pattern had changed to a type 1 pattern.
valuation of incidence of AF. The occurrence of spon-
aneous AF was evaluated by clinical follow-up (every
onth), in which the patient’s symptoms were observed and
4-h Holter recordings without any drugs were performed.
ontinuous ECG monitoring was also performed for 2 to 3
eeks during admission.
nalysis of SCN5A mutation. This study was performed
n compliance with guidelines for human genome studies of
he Ethics Committee of Okayama University. Informed
onsent was obtained from all patients. All exons of SCN5A
ere amplified by polymerase chain reaction (PCR) from
eoxyribonucleic acid (DNA) isolated from peripheral leu-
ocytes of the patients. Genomic DNA was extracted from
eripheral blood leucocytes using a DNA extraction kit
Gentra, Minneapolis, Minnesota) and was stored at30°C
Abbreviations
and Acronyms
AF  atrial fibrillation
BrS  Brugada syndrome
CS  coronary sinus
CT  conduction time
EP  electrophysiology/
electrophysiological
ERP  effective refractory
period
FH  family history of
sudden death
ICD  implantable
cardioverter-defibrillator
PCR  polymerase chain
reaction
RAA  right atrial
appendage
RAF  repetitive atrial
firing
SCN5A  pore-forming
region of the human
cardiac sodium channel
VF  ventricular fibrillationntil use. rTwenty-seven exons of the SCN5A gene were amplified
ith previously reported intronic primers (14). SCN5A gene
xon 1 is a noncoding region, and this region was not
nalyzed in this study. Exons 6, 17-1 Sense, 21, and 25 were
ot able to be amplified sufficiently by the primers, and we
esigned new intronic primers. The following primers were
sed in this study: 5=-GTT ATC CCA GGT AAG ATG
CC-3= (sense) and 5=-TGG TGA CAG GCA CAT
CG AAG-3= (antisense) for exon 6, 5=-AAG CCT CGG
GC TGT TTG TCA CA-3= (sense) for exon 17-1,
=-TGC CTG GTG CAG GGT GGA AT-3= (sense) and
=-ACT CAG ACT TAC GTC CTC CTT C-3= (anti-
ense) for exon 21, and 5=-TCT TTC CCA CAG AAT
GA CAC C-3= (sense) and 5=-AAG GTG AGA TGG
AC CTG GAG-3= (antisense) for exon 25. Polymerase
hain reaction was performed in 25-l reaction volumes
ontaining 50 ng of genomic DNA, 20 pmol of each primer,
.8 mM dNTPs, 1 X reaction buffer, 1.5 mM MgCl2, and
.7 U of AmpliTaq Gold DNA polymerase (Applied
iosystems, Foster City, California) or TAKARA Taq
Takara Bio Inc., Otsu, Shiga, Japan). All PCR products
ere purified with a PCR products pre-sequencing kit
Amersham Life Science, Buckinghamshire, United King-
om), reacted with a Big Dye Terminator FS ready-reaction
it (Applied Biosystems), and analyzed on an ABI
RISM3130xl sequencer (Applied Biosystems). Mutations
ere analyzed at least 3 times by independent PCR ampli-
cation and sequencing. Polymerase chain reaction products
ere subjected to single-strand conformation polymorphism
nalysis followed by direct sequence analysis.
P study. After obtaining written informed consent from
atients, an EP study was performed as described previously
6,15,16) in all patients. In brief, after right femoral and
ight jugular venous access had been obtained, 3 quadripolar
lectrode catheters (6-F) with an interelectrode distance of
mm (EP Technologies, Boston Scientific, Inc., Sunnyvale,
alifornia) were positioned in the right atrial appendage
RAA), His bundle region, and right ventricle, and an
ctopolar catheter (6-F) with an interelectrode distance of
.5 mm (EP Technologies, Boston Scientific, Inc.) was
ositioned in the coronary sinus (CS). To reduce the
ifferences among patients, the proximal electrode of CS
atheter was positioned at the CS ostium and the distal
lectrode was located at the lateral wall of the left atrium in
ll patients. An extra-stimulus (S2) was delivered after 8
eats of drive pacing (S1) at a basic cycle length of 600 ms.
he S1-S2 interval was decreased in 10-ms steps until the
ffective refractory period (ERP) of the RAA was reached.
inus node recovery time was also measured during the EP
tudy.
The parameters during EP study were as follows: 1) ERP
f the RAA by atrial extra-stimulus testing; 2) interatrial
onduction time (CT) measured by CT from the stimulus at
he right atrium to atrial deflection at the distal portion of
he CS; 3) the duration of local atrial electrogram (A)
ecorded at atrial pacing site; 4) repetitive atrial firing (RAF)
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March 25, 2008:1169–75 AF and Brugada Syndromeefined as occurrence of 2 or more premature atrial com-
lexes after atrial stimulation; and 5) induced AF defined
s AF that was induced by extrastimulus and persisted
or 30 s (6,17–19). If RAF or AF was induced during
he paired pacing, S2 was no longer decreased and ERP
as defined as the minimum S2 interval that induced RAF
r AF.
Programmed electrical stimulation was also performed at
he ventricle to induce VF. As described previously (15),
rogrammed electrical stimulation was performed at an
ntensity twice threshold and 2-ms in duration through the
istal electrodes in the right ventricular apex, free-wall
egion, septal region of the right ventricular outflow tract,
nd posterolateral wall of the left ventricle using pulse
enerator as described before. The protocol of ventricular
timuli included up to 3 extrastimuli at the basic cycle length
f 600 ms and 400 ms and the minimum coupled extra-
timuli of 180 ms.
tatistical analysis. Data are expressed as mean values 
tandard deviation. Student t test was performed to test for
tatistical differences between 2 unpaired mean values, and
ategorical data and percentage frequencies were analyzed
y the chi-square test (SPSS II for Windows, SPSS Inc.,
hicago, Illinois). A value of p  0.05 was considered to be
tatistically significant.
esults
atients’ characteristics. The population consisted of a
otal of 73 probands. None of the patients in this study were
embers of the same family. Patients’ characteristics are
ummarized in Table 1. Spontaneous AF was documented
n 10 (13.7%) of the patients and VF was documented in 13
17.8%) of the patients. Nineteen (26.0%) of the patients
ad an FH, and syncopal episodes occurred in 20 (27.4%) of
he patients. Gene analysis revealed that SCN5A mutation
as present in 15 (20.5%) of the patients. Spontaneous type
ECG was observed in 23 (31.5%) of the patients. In EP
tudy, VF was induced in 34 (47%) of the patients and 33
45.2%) of the patients had received ICD implantation.
atients’ Characteristics (n  73)
Table 1 Patients’ Characteristics (n  73)
Men/women 72/1
Age (yrs) 49.5  12.0
Syncopal episode (%) 20 (27.4%)
Documented VF (%) 13 (17.8%)
Spontaneous AF (%) 10 (13.7%)
Family history of sudden death (%) 19 (26.0%)
SCN5A mutation (%) 15 (20.5%)
Spontaneous type 1 ECG 23 (31.5%)
VF induction during EP study (%) 34 (46.6%)
ICD implantation (%) 33 (45.2%)
alues are mean  SD or number of patients.
AF  spontaneous documented atrial fibrillation; ECG  electrocardiogram; EP  electrophys-g
ological; ICD implantable cardioverter defibrillator; SCN5A pore-forming region of the human
ardiac sodium channel; VF  ventricular fibrillation.ircadian variation of spontaneous AF and VF. Sponta-
eous AF episodes were detected at night (12:00 AM to 6:00
M) in 7 (70%) of the 10 patients with documented AF and
of 10 patients in the daytime (6:00 AM to 6:00 PM).
ocumented VF episodes were observed in 13 patients (46
pisodes). Among them, 7 patients (55%) (22 episodes
48%]) were detected at night (12:00 AM to 6:00 AM), and 2
atients (15%) (7 episodes [15%]) in the daytime (6:00 AM
o 6:00 PM).
linical and genetic differences in BrS patients with
F. Clinical and genetic parameters were compared in BrS
atients with spontaneous AF and those without spontane-
us AF (Table 2). None of the patients in this study showed
hronic AF. Age was not different between the groups. In
he clinical parameters, syncopal episode, documented VF,
nd spontaneous type 1 ECG were observed in larger
ercentage of patients with spontaneous AF (syncope:
0.0% vs. 22.2%, p  0.03; documented VF: 40.0% vs.
4.3%, p  0.05; and spontaneous type 1 ECG: 60.0% vs.
7.0%, p 0.04). However, FH, SCN5A mutation, and VF
nduction during EP study were not related to spontaneous
F episodes (Table 2).
P parameters in BrS patients with AF. In EP study,
here was no significant difference between the ERP of the
AA in the AF () group (254.3  44.7 ms) and that in
he AF () group (243.9  25.5 ms). However, CT was
ore prolonged in the AF group at S1 (CT at S1: 138.4 
3.8 ms vs.122.3  20.1 ms, p  0.03) and at S2 (172.4 
3.3 ms vs. 154.2  18.0 ms, p  0.03). Sinus node
ecovery time was significantly prolonged in the AF ()
roup (1,971  1,007 ms vs. 1,288  488 ms, p  0.01).
ther parameters, including RAF, induction of AF, and
ocal atrial electrograms (A1: A at S1 and A2: A at S2) were
ot different between the groups (Table 2).
linical and EP parameters in BrS patients with SCN5A
utation. Next we examined the relationships of genetic
utation with clinical and EP parameters in patients
ith BrS. None of the clinical parameters (age, syncopal
pisode, documented VF, spontaneous AF, FH, sponta-
eous type 1 ECG, and ICD implantation) were different
n patients with SCN5A mutation and patients without
CN5A mutation. However, AF induction (in 46.7% of
he patients with SCN5A mutation and in 20.7% of the
atients without SCN5A mutation, p  0.05), CT at S1
138.1  18.1 ms with SCN5A mutation and 121.5 
0.9 ms without SCN5A mutation, p  0.03), CT at S2
167.9  14.2 ms with SCN5A mutation and 153.4 
1.3 ms without SCN5A mutation, p  0.03), local A2
103.9  17.4 ms with SCN5A mutation and 89.8  18.7
s without SCN5A mutation, p  0.03), and sinus node
ecovery time (1,682  1,036 ms with SCN5A mutation
nd 1,300  433 ms without SCN5A mutation, p  0.04)
uring EP study were significantly different between the
roups (Table 3).
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AF and Brugada Syndrome March 25, 2008:1169–75linical, genetic, and EP parameters in BrS patients with
pontaneous type 1 ECG. Next we examined the rela-
ionship of the basal ECG pattern to the clinical, genetic,
nd EP parameters in patients with BrS. Spontaneous
ype 1 ECG was observed in 23 of the patients (31.5%)
nd drug (pilsicainide)-induced type 1 ECG (type 2 or 3
CG before the drug administration) in the remaining
Characteristics of Patients With and Without AF
Table 2 Characteristics of Patients With an
With
Clinical/genetic parameters
Number of patients (men/women) 63 (
Age (yrs) 48.4
Syncopal episode (%) 14 (
Documented VF (%) 9 (
Family history of sudden death (%) 17 (
SCN5A mutation (%) 13 (
Spontaneous type 1 ECG (%) 17 (
VF induction during EP study (%) 29 (
ICD implantation (%) 27 (
EP parameters of the atrium
RAF 31 (
AF induction 14 (
ERP (ms) 243.9
CT at S1 (ms) 122.3
CT at S2 (ms) 154.2
A1 (ms) 65.7
A2 (ms) 92.4
A2/A1 1.42
Sinus node recovery time (ms) 1,288
Values are mean  SD or number of patients.
A1  local atrial potential at S1; A2  local atrial potential at S2;
repetitive atrial firing; other abbreviations as in Table 1.
Clinical and EP Parameters in Patients With and
Table 3 Clinical and EP Parameters in Patie
SCN5A M
Clinical parameters
Number of patients (men/women) 58 (5
Age (yrs) 49.6
Syncopal episode (%) 15 (2
Documented VF (%) 9 (1
Spontaneous AF (%) 8 (1
Family history of sudden death (%) 13 (2
Spontaneous type 1 ECG (%) 16 (2
VF induction during EP study (%) 30 (5
ICD implantation (%) 26 (4
EP parameters of the atrium
RAF 29 (5
AF induction 12 (2
ERP (ms) 240.2
CT at S1 (ms) 121.5
CT at S2 (ms) 153.4
A1 (ms) 64.5
A2 (ms) 89.8
A2/A1 1.41
Sinus node recovery time 1,300Values are mean  SD or number of patients.
Abbreviations as in Tables 1 and 2.0 patients (68.5%) in this study. Spontaneous AF was
ignificantly more observed in patients with spontaneous
ype 1 ECG (26.1% vs. 8.0%, p  0.04). Documented VF
ended to be more observed but not statistically signifi-
ant (30.4% vs. 12.0%, p  0.06). Other parameters
ncluding age, syncopal episodes, FH, frequency of
CN5A mutation, VF induction, ICD implantation, and
hout AF
F With AF p Value
10 (10/0)
.5 53.7 14.2 NS
) 6 (60.0%) 0.03
) 4 (40.0%) 0.05
) 2 (20.0%) NS
) 2 (20.0%) NS
) 6 (60.0%) 0.04
) 5 (50.0%) NS
) 6 (60.0%) NS
) 6 (60.0%) NS
) 5 (50.0%) NS
.5 254.3 44.7 NS
.1 138.4 23.8 0.03
.0 172.4 33.3 0.03
.9 72.5 20.4 NS
.9 99.2 21.8 NS
5 1.39 0.24 NS
8 1,971 1,007 0.01
teratrial conduction time; ERP  effective refractory period; RAF 
hout SCN5A Mutation
ith and Without SCN5A Mutation
() SCN5A Mutaion () p Value
15 (15/0)
3 47.5 14.5 NS
5 (33.3%) NS
4 (26.7%) NS
2 (13.3%) NS
6 (40.0%) NS
7 (46.7%) NS
4 (26.7%) NS
7 (46.7%) NS
8 (53.3%) NS
7 (46.7%) 0.05
2 264.5 35.6 NS
9 138.1 18.1 0.03
3 167.9 14.2 0.03
2 73.0 11.4 NS
7 103.9 17.4 0.03
6 1.45 0.20 NS
1,682 1,036 0.04d Wit
out A
62/1)
 11
22.2%
14.3%
27.0%
20.6%
27.0%
46.0%
42.9%
49.2%
22.2%
 25
 20
 18
 12
 18
 0.2
 48Wit
nts W
utaion
7/1)
 11.
5.9%)
5.5%)
3.8%)
2.9%)
7.6%)
1.7%)
4.8%)
0.0%)
0.7%)
 24.
 20.
 21.
 13.
 18.
 0.2
 433
a
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March 25, 2008:1169–75 AF and Brugada Syndromell EP parameters were not different between the groups
Table 4).
linical, genetic, and EP parameters in BrS patients with
nd without VF episodes. Finally, we examined the rela-
ionships of disease severity (documented VF) with other
linical, genetic, and EP parameters in BrS patients. Spon-
aneous AF was observed in a large percentage of patients
Clinical, Genetic, and EP Parametersin Patients With and Without Spontaneous Type
Table 4 Clinical, Genetic, and EP Parametein Patients With and Without Spont
Type 2
Clinical/genetic parameters
Number of patients (men/women) 50 (4
Age (yrs) 49.7
Syncopal episode (%) 12 (2
Documented VF (%) 6 (1
Spontaneous AF (%) 4 (8
Family history of sudden death (%) 13 (2
SCN5A mutation (%) 8 (1
VF induction during EP study (%) 20 (4
ICD implantation (%) 19 (3
EP parameters of the atrium
RAF 26 (5
AF induction 11 (2
ERP (ms) 246.2
CT at S1 (ms) 122.9
CT at S2 (ms) 155.8
A1 (ms) 65.3
A2 (ms) 91.1
A2/A1 1.4
Sinus node recovery time (ms) 1,310
Values are mean  SD or number of patients.
Abbreviations as in Tables 1 and 2.
Clinical, Genetic, and EP Parametersin Patients With and Without Documented VF E
Table 5 Clinical, Genetic, and EP Parametein Patients With and Without Docum
Documente
Clinical/genetic parameters
Number of patients (men/women) 60 (59
Age (yrs) 48.3
Spontaneous AF (%) 6 (10
Family history of sudden death (%) 17 (28
SCN5A mutation (%) 11 (18
Spontaneous type 1 ECG (%) 16 (26
VF induction during EP study (%) 28 (46
ICD implantation (%) 20 (33
EP parameters of the atrium
RAF 29 (48
AF induction 12 (20
ERP (ms) 242.0
CT at S1 (ms) 121.9
CT at S2 (ms) 153.7
A1 (ms) 66.1
A2 (ms) 91.6
A2/A1 1.4
Sinus node recovery time 1,313Values are mean  SD or number of patients.
Abbreviations as in Tables 1 and 2.ith VF episodes (30.8%) in comparison with that seen in
atients without VF episodes (10.0%) (p  0.05), but the
requency of SCN5Amutation was not different between the
roups (Table 5). Spontaneous type 1 ECG tended to be
ore observed in patients with VF episodes but not statis-
ically significant (p  0.06). As for the EP parameters,
RP at RAA was not different, but the rate of AF induction
G
us Type 1 ECG
CG Type 1 ECG p Value
23 (23/0)
0 47.8 12.0 NS
8 (34.8%) NS
7 (30.4%) NS (p  0.06)
6 (26.1%) 0.04
6 (26.1%) NS
7 (30.4%) NS
14 (60.9%) NS
14 (60.9%) NS
11 (47.8%) NS
8 (34.8%) NS
4 242.9 32.0 NS
8 128.6 17.4 NS
3 157.6 16.9 NS
1 69.9 15.8 NS
4 99.2 20.8 NS
1.4 0.2 NS
1,523 855 NS
e
d VF Episode
) Documented VF () p Value
13 (13/0)
52.8 11.1 NS
4 (30.8%) 0.05
2 (15.4%) NS
4 (30.8%) NS
7 (53.8%) NS (p  0.06)
6 (46.2%) NS
13 (100%) 0.01
8 (61.5%) NS
7 (53.8%) 0.03
261.1 34.8 NS
137.6 24.6 0.02
171.3 33.9 0.02
68.6 8.5 NS
100.4 15.0 NS
1.5 0.2 NS
1,658 937 NS1 EC
rs
aneo
or 3 E
9/1)
 12.
4.0%)
2.0%)
.0%)
8.0%)
6.0%)
0.0%)
8.0%)
2.0%)
2.0%)
 27.
 22.
 22.
 12.
 18.
 0.3
 460pisod
rs
ente
d VF (
/1)
12.0
.0%)
.3%)
.3%)
.7%)
.7%)
.3%)
.3%)
.0%)
26.2
19.6
16.8
14.1
19.8
0.3
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AF and Brugada Syndrome March 25, 2008:1169–75as significantly higher (53.8% vs. 20.0%, p  0.03) and
T was prolonged in patients with VF episodes (CT at S1:
37.6  24.6 ms vs. 121.9  19.6 ms, p  0.02; CT at S2:
71.3  33.9 ms vs. 153.7  16.8 ms, p  0.02) (Table 5).
inus node recovery time was not different between the
roups (p  0.07).
iscussion
he present study demonstrated that BrS patients with
pontaneous AF have more severe clinical and EP back-
rounds but not associated with family history or mutations
f the gene encoding the cardiac sodium channel, SCN5A.
lectrical vulnerability across the heart may be closely
ssociated with spontaneous AF and VF occurrence in BrS
atients.
F in BrS. It has been reported that spontaneous AF is
ften observed in patients with BrS. The incidence of AF in
his syndrome has been reported to be 10% to 53% (1,4,6).
n this study, the incidence of spontaneous AF was 13.7%
nd most cases (70%) were documented at night. Matsuo
t al. (20) reported that VF in patients with BrS was most
requently detected in the midnight to early morning period
uring sleep. Our finding of a circadian pattern in sponta-
eous AF and VF episodes is in agreement with their
ndings, and these findings suggested that nocturnal vagal
ctivity and withdrawal of sympathetic activity may play an
mportant role in arrhythmogenesis in both AF and VF
ccurrence in this syndrome.
The treatment for AF in BrS is an important issue. It has
een reported that quinidine sulfate, isoproterenol, cilosta-
ole (1), and bepridil chloride (21,22) are recommended in
rugada patients with repeated VF by a mechanism of
ugmenting the calcium current or reducing the Ito current.
n this study, none of the patients received antiarrhythmic
rugs for AF because their episodes were paroxysmal with
ew symptoms. However, 2 AF patients that experienced
ecurrent VF episodes had received antiarrhythmic drugs to
revent recurrent VF (1 patient received quinidine sulfate
.3 g and the other received bepridil hydrochloride 100 mg).
hile these patients never experienced AF episodes with
aking these drugs, indicating antiarrhythmic drugs that
ere effective to prevent VF might be also effective in AF.
P parameters in patients with BrS. It has also been
eported that atrial vulnerability was increased in patients
ith BrS, compared with that in a normal control group (6).
mong the various indexes of EP parameters, we found the
nteratrial conduction delay (CT) was significantly increased
n BrS patients with AF, indicating that global conduction
f the atrial myocardium was impaired. Interestingly, atrial
ulnerability (induced AF) was more impaired in BrS
atients with VF episodes, indicating that electrical vulner-
bility may be across the whole heart including the atrium
nd ventricle. The fact that patients with AF have more
pisodes of VF or syncopal episodes supports this possibility.There was no difference in VF inducibility between the
atients with and without documented VF. In this study, all
atients who had documented VF experienced at least 1 VF
pisode before ICD implantation; therefore, asymptomatic
atients never experienced VF attacks during the follow-up
eriod after ICD implantation. These results indicate that
F inducibility during EP study has a low specificity to
dentify high-risk BrS patients as reported before (23).
CN5A mutation is not associated with AF in BrS. The
ene encoding the cardiac sodium channel, SCN5A, has
een reported to be linked causally to BrS. We speculated
F is more common in patients with SCN5A mutation, but
e found no difference between patients with SCN5A
utation and those without SCN5A mutation in spontane-
us AF episodes or in other clinical parameters (spontane-
us VF, syncopal episode, FH, and spontaneous type 1
CG). The reason is still unclear, but this finding is perhaps
f most interest. These results indicate that a defect in the
CN5A gene is not associated with AF events or with VF
vents as was previously reported (1), suggesting that
enetic analysis is not useful for risk stratification.
linical implications. This study showed that spontane-
us AF and atrial vulnerability are important predictors of
F events that cause sudden cardiac death. The fifth-
eneration ICD is preferable for patients with BrS, even for
rS patients who have never experienced an attack of AF,
ecause atrial vulnerability is common and AF could occur
uring the follow-up period.
tudy limitations. The number of patients in this study
as small, and further study is needed to reach definitive
onclusion regarding the impact of AF episodes for BrS.
oreover, we analyzed only the coding regions of SCN5A
or mutations in this study, and the possibility of mutations
ccurring in regions of the gene other than coding regions
annot be excluded. The functional impact has not been
tudied for all identified SCN5A mutations; therefore, a causal
elationship in individual patients has not been proved yet.
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